Jordi Fàbrega has held various positions in the pharmaceutical industry and has several years of consultancy experience in the Pharma and Med Tech sectors. As a consultant he was responsible for the execution and development of over 100 projects. Prior to joining Connecta, Jordi was Director of Business Development at Biocat. He was responsible for the definition and progress of the cluster initiatives to develop and promote the life science sector in Catalonia. He has broad experience in strategy, business development, marketing, market access and regulatory. Jordi holds a BS in Pharmacy and a BS in Food Science and Technology, an MSc in Pharmaceutical and Parapharmaceutical Industries and an MBA from the ESADE Business School.

Josep Prous Jr. is Co-Founder and Chief Scientific Officer at CONNECTA Therapeutics, Co-Founder and Executive Director of the Prous Institute for Biomedical Research and Strategic Advisor to life sciences organizations, where he is responsible for the design and implementation of in silico drug discovery and safety technologies. Previously, he served as Co-Founder and Executive Director of Bionfofate, which was acquired by Clarivate Analytics in 2021 and Vice President and Chief Scientific Officer of the Healthcare and Science business of Thomson Reuters, following the acquisition of his former company Prous Science by Thomson Scientific in 2007. Josep has longstanding experience in establishing fruitful collaborations with biomedical research organizations. He holds a BS in Chemistry and an MBA from the ESADE Business School and completed his Ph.D. doctoral thesis, spearheading a medicinal chemistry project for the discovery of new drugs for Alzheimer's disease.

Sara Secall is responsible for building the Biotech Portfolio in Inveready. Sara has an extensive international career investing in technology. She was involved in investing and exiting several Venture Capital investments while working for Chevron Technology Ventures, the corporate venture capital group based in California with USD 210 MM under management. Prior to joining Inveready, as Director of Spin Outs for the University of Barcelona, she was involved in starting and financing over 25 technology startups and negotiated numerous technology licenses, mainly in the biotechnology sector. She has worked extensively in the USA, Latin America and Europe. Sara holds a BS in Chemistry, MSc in Environmental Sciences from Indiana University and an MBA from the London Business School.

Dr. Hagerman is internationally recognized as both a clinician and researcher in the fragile X field. She has carried out multiple targeted treatment trials in FXS and autism including a controlled trial of Arbaclofen, minocycline, ganaxolone, sertraline and mGluR5 antagonists developed by Roche and Novartis.

The Dierssen lab is centered on understanding cognition and behavior and how they are perturbed in intellectual disability. Her lab uses this knowledge to discover new therapeutic targets. Dr. Dierssen has published more than 150 papers, with a h-index of 43 and major research papers in the upper 10% impact factor journals in her field, in international peer reviewed journals and 20 book chapters.

Marta Pascual-Gilabert has longstanding experience in the chemical and biopharmaceutical sectors, where she has held several scientific positions in the field of drug discovery, drug development and project management, leading multidisciplinary projects and teams. Marta’s experience encompasses drug design, process development and optimization of chemical, biocatalytic and chemoenzymatic routes of synthesis, preclinical and clinical development of investigational medicinal products and medical foods, along with regulatory affairs and intellectual property protection. She is leading the company’s R&D projects, providing strategic vision and guidance to foster the pipeline, implement the strategy and achieve mid- and long-term preclinical and clinical milestones. Marta holds a BS in Chemistry, a MSc in Organic Chemistry, a postgraduate degree in Regulatory Affairs, and a PhD in Pharmacy and Food Sciences from the University of Barcelona.

Irene Domingo Pascual is a Biologist with a strong background in life sciences. She holds a Master’s degree in Biotechnology Business Management from CESIF, which complements her scientific training with expertise in business strategy, innovation, and project execution. Earlier in her career, Irene gained hands-on research experience as part of a scientific group specializing in muscle wasting and cachexia associated with chronic respiratory diseases and lung cancer. She has also worked in the pharmaceutical industry, where she held roles in Quality Control and Quality Assurance. With a profile that combines scientific expertise and industry experience, she is currently Senior R&D Project Manager at CONNECTA Therapeutics, coordinating the preclinical and clinical programs, ensuring strategic alignment, efficient execution, and cross-functional collaboration across scientific, clinical, and operational teams.

Gala Martín is a professional in Biotechnology, specialising in neuroscience and machine learning. She holds an academic trajectory at IQS, Ramon Llull University where she gained laboratory and experimental data analysis skills. Her education in biotechnology was complemented by fundamental learning of project management and strengthened by an involvement at the Norwegian University of Science and Technology (NTNU) where she deepened her focus on neurosciences by learning about techniques for measuring brain activity.